GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MyoKardia Inc (NAS:MYOK) » Definitions » Net Margin %

MyoKardia (MyoKardia) Net Margin % : 0.00% (As of Sep. 2020)


View and export this data going back to 2015. Start your Free Trial

What is MyoKardia Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. MyoKardia's Net Income for the three months ended in Sep. 2020 was $-84.74 Mil. MyoKardia's Revenue for the three months ended in Sep. 2020 was $0.00 Mil. Therefore, MyoKardia's net margin for the quarter that ended in Sep. 2020 was 0.00%.

The historical rank and industry rank for MyoKardia's Net Margin % or its related term are showing as below:


MYOK's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -157.59
* Ranked among companies with meaningful Net Margin % only.

MyoKardia Net Margin % Historical Data

The historical data trend for MyoKardia's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MyoKardia Net Margin % Chart

MyoKardia Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Net Margin %
Get a 7-Day Free Trial -161.60 -24.73 -498.25 -201.73 -

MyoKardia Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MyoKardia's Net Margin %

For the Biotechnology subindustry, MyoKardia's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MyoKardia's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MyoKardia's Net Margin % distribution charts can be found below:

* The bar in red indicates where MyoKardia's Net Margin % falls into.



MyoKardia Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

MyoKardia's Net Margin for the fiscal year that ended in Dec. 2019 is calculated as

Net Margin=Net Income (A: Dec. 2019 )/Revenue (A: Dec. 2019 )
=-276.213/0
= %

MyoKardia's Net Margin for the quarter that ended in Sep. 2020 is calculated as

Net Margin=Net Income (Q: Sep. 2020 )/Revenue (Q: Sep. 2020 )
=-84.744/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MyoKardia  (NAS:MYOK) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


MyoKardia Net Margin % Related Terms

Thank you for viewing the detailed overview of MyoKardia's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


MyoKardia (MyoKardia) Business Description

Traded in Other Exchanges
N/A
Address
1000 Sierra Point Parkway, Brisbane, CA, USA, 94005
MyoKardia Inc is a US-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company mainly focuses on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It uses its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. The company's products include MYK-461 s an orally administered small molecule to reduce excessive cardiac muscle contractility leading to HCM.
Executives
Anastasios Gianakakos director, officer: President and CEO 333 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Denelle J Waynick officer: General Counsel C/O MYOKARDIA, INC. 1000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mary B Cranston director C/O VISA INC., P.O. BOX 8999, SAN FRANCISCO CA 94128-8999
Mark L Perry director 176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941
David P Meeker director C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Wendy L Yarno director
Sunil Agarwal director 60 LEVERONI COURT, NOVATO CA 94949
Kimberly J Popovits director 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Jake Bauer officer: Chief Business Officer C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Taylor C. Harris officer: Chief Financial Officer 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
William Fairey officer: See Remarks C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043
Cynthia J Ladd officer: General Counsel C/O AGY THERAPEUTICS INC, 290 UTAH AVE, SOUTH SAN FRANCISCO CA 94080
Robert Scott Mcdowell officer: Chief Scientific Officer C/O MYOKARDIA, INC., 333 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
June Lee officer: EVP, Chief Development Officer C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Anofi 10 percent owner 46 AVENUE DE LA GRANDE ARMEE, PARIS I0 75017